SGLT2 Inhibitors in Patients With Polycystic Ovarian Syndrome
Status:
Enrolling by invitation
Trial end date:
2021-04-30
Target enrollment:
Participant gender:
Summary
Polycystic ovary syndrome (PCOS) is a common endocrine disorder, with a prevalence of 5% to
15% in premenopausal women. Patients with PCOS presents as abnormal menstruation, ovulation
disorders and/or hyperandrogenemia, and often accompanied by insulin resistance and other
metabolic abnormalities. Metformin has been clarified as an option in patients with PCOS.
However, the clinical responses to metformin are limited and different. Sodium glucose
co-transporter 2 (SGLT2) inhibitors are novel drugs for the treatment of type 2 diabetes,
with weight loss, reducing insulin resistance and cardiovascular benefits. Limited data is
available on the efficacy of SGLT2 inhibitors in patients with PCOS.